PCVXPCVX

$63.4-2.0%11월 13일 종가 기준

시가총액 $10.0B

3달 전보다 +7.9%

최고 $73.82최저 $52.98

세로선 = 임상·딜 이벤트 · 차트 위에서 스크롤하면 확대·축소, 확대 중엔 가로로 넘겨볼 수 있어요

매수 의견AI 점수 88 / 100

무세포 단백질 합성 플랫폼으로 세균성 감염병 예방 백신을 개발해요.

We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are re-engineering the way highly complex vaccines are made through the XpressCF™ cell-free protein synthesis platform. Our system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits that are beyond the capabilities of conventional approaches.

진행 중인 임상과 AI 예측

Phase 3VAX-31 폐렴구균 및 독감백신 병용투여 임상진행 중A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
87%
Phase 350세 이상 대상 폐렴구균 백신 VAX-31 안전성 임상진행 중Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
79%
Phase 1건강한 성인 대상 백신 후보물질 VAX-A1 1상 임상모집 중A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
48%
Phase 2VAX-31 영아 대상 폐렴구균 백신 1/2상 임상진행 중A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
88%
Phase 3VAX-31 성인 폐렴구균 백신 면역원성 및 안전성 임상진행 중Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
82%
Phase 2VAX-24 24가 폐렴구균 백신 영아 대상 안전성 임상완료Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
88%
Phase 2VAX-31 성인 31가 폐렴구균 단백접합 백신 임상완료Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
76%
Phase 2고령자 대상 24가 폐렴구균 백신 VAX-24 안전성 및 효능 임상완료Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
78%
Phase 2성인 대상 24가 폐렴구균 단백접합 백신(VAX-24) 임상완료Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
76%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.

홈으로 돌아가기